OCTALFA is active and involved in supporting entrepreneurship in France. Its purpose is to promote academic and industrial research in the healthcare sector. Its missions are to identify inventions and expertises that will benefit to patients, coordinate research and feasibility studies prior to the inception of the company, define its strategy, set up the management and fund R&D until the market introduction of products or signing of structuring partnerships.

OCTALFA therefore supports companies until they achieve profitability, are sold or receive backing from an industrial or financial organisation.



For 6 to 12 months, alongside the inventor, we approve the feasibility, business model and strategy of the innovative company plan


If the project is confirmed following the incubation phase, we create a startup with the inventor


We fund companies created with a long-term vision (seed capital, first and second round)


We define strategy, then structure, grow and manage companies created


  • ORPHELIA Pharma

    SINCE 2015
    Biopharmaceutical company dedicated to the development and commercialization of new pediatric formulations of neurology and oncology compounds

  • Alizé Pharma 3

    SINCE 2014
    Biopharmaceutical company developing innovative peptides for the treatment of osteoporosis and certain bone diseases

  • Mathym

    INCEPTED IN 2013
    Nanotechnology company dedicated to the development, manufacturing and commercialization of innovative colloidal solutions

  • Nightswapping

    SINCE 2014
    Startup company developing novel collaborative tourism tools

  • Eyebrain

    FROM 2011 TO 2016
    Medtechcompany dedicated to the development, manufacturing and marketing of eyetrackers. Liquidation in 2016.

  • JUVISE Pharmaceuticals

    SINCE 2011
    Pharmaceutical company marketing products to treat psychiatric, inflammatory and respiratory diseases.

  • Docea Power

    FROM 2010 TO 2015
    EDA company dedicated to the development and commercialization of solutions to model and optimize the power consumption of electronic chips. Acquired by Intel in 2015

  • OREGA Biotech

    INCEPTED IN 2010
    Biotechnology company dedicated to the research and development of novel antibodies for cancer immunotherapy


  • OREGA Biotech’s interleukin-17 patent to be granted in the US

    Receipt of a Notice of Allowance from USPTO for a strategic patent application related to OREGA’s IL-17 program

  • IL-17B program to be presented at AACR 2017

    OREGA will present latest in vivo data of its IL-17B program on April 3 at the upcoming AACR annual conference to be held in Washington DC

  • Meet us at Bio-Europe Spring 2017

    Gilles Alberici and Jeremy Bastid will attend the Bio-Europe Convention to be held In Barcelona, March 20-22, 2017.

  • Merry Christmas and Happy New year 2017 !

    initiative OCTALFA wishes you a Merry Christmas and a Happy New Year 2017 !

  • Alize Pharma to attend J.P. Morgan

    J.P. Morgan 35th Annual Healthcare Conference 2017 will take place 9 – 13 January 2017 in San Francisco, CA, USA1

  • Mathym closes its second financing round

    The proceeds will be used to implement the first manufacturing line and conduct the R&D programs

  • Antagene joints Cerba Healthcare

    ANTAGENE joins CERBA VET to form a European veterinary diagnostic leader

  • Alizé Pharma III presents preclinical results in osteoporosis

    The HBD1 peptide exhibited strong bone anabolic potency in a model of post-menopausal osteoporosis